As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The ORNOVA Division of Hetero Healthcare focuses on orthopaedic, pain management, and musculoskeletal healthcare, offering therapeutic solutions that support mobility, recovery, and overall bone and joint health.
Its portfolio addresses key areas such as pain and inflammation, osteoarthritis, joint and muscle-related conditions, bone health, and nutritional support, catering to both acute and long-term musculoskeletal care.
Backed by Hetero Healthcare’s commitment to quality, accessibility, and patient-centric care, ORNOVA strives to provide dependable therapeutic options that support effective clinical management and better patient outcomes.
View by-